📰 Albireo News
Albireo News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Albireo. Real-time updates on events, politics, business and more.
March 2, 2023
Ipsen completes acquisition of Albireo, expanding the scope of its Rare Disease portfolio Bringing medicines to patients with rare liver disease, a growth opportunity for IpsenLead asset Bylvay® (odevixibat)
February 22, 2023
Ipsen extends expiration date of tender offer for Albireo Pharma, Inc. to 1 March 2023 Extension allows for the satisfaction of the HSR Act related condition as outlined in the Merger AgreementAlbireo stockholders are
January 26, 2023
NEW YORK, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York...
January 9, 2023
Transaction focused on Bylvay (odevixibat), the first-approved treatment in progressive familial intrahepatic cholestasis in U.S. and E.U., with potential in other rare diseases Acquisition
January 9, 2023
Ipsen S.A. entered into a definitive merger agreement to acquire Albireo Pharma, Inc. for approximately $870 million on January 9, 2023. Ipsen to commence cash tender offer to acquire all issued and... |
December 25, 2022
The winter skies offer the opportunity to observe an interesting kind of astronomical object called a double star.
November 30, 2022
BOSTON, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, today announced
October 11, 2022
Highly statistically significant improvement in pruritus primary endpoint (p=0.002)Significant reductions in key secondary endpoint of serum bile acid levels (p=0.001)Substantial improvements in multiple
September 6, 2022
Positive Agenzia Italiana del Farmaco (AIFA) decision provides reimbursed access to the first medicine available for the treatment of all types of PFIC, a rare and devastating disorder that affects
March 23, 2022
Established in Sweden as a small spinout of AstraZeneca in 2008, Albireo always had big ambitions.